肺癌循环肿瘤源性生物标志物
| 作者: |
1,1,1,2Taenzer Aline
1 Department of Tumour Biology, Centre of Experimental Medicine, University Cancer Center Hamburg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany 2 University Medical Centre, University Montpellier 1, Saint-Eloi Hospital, Institute of Research in Biotherapy, Laboratory of Rare Human Circulating Cells, Montpellier, France; University Medical Centre, Laboratory of Cell and Hormonal Biology, Arnaud de Villeneuve Hospital, Montpellier, France; University Institute of Clinical Research UM1 - EA2415 - Epidemiology, Biostatistics & Public Health, France |
| 通讯: |
Pantel Klaus
Email: pantel@uke.uni-hamburg.de |
摘要
美国国立卫生研究院生物标志物定义工作组将生物标志物定义为“一种具有能客观测量同时可用于评价一般生物过程、发病过程或医疗干预相关药物反应的指示物”[1]。大量正在进行的肺癌相关研究致力于探讨用于早期诊断和高风险预测的气道上皮细胞、痰液、呼气、尿液和血液中的生物标志物。在此，着重评述肺癌的循环生物标志物，尤其是循环肿瘤细胞（circulating tumor cells，CTCs）与循环核酸（circulating nucleic acids，CNAs）
关键词：
肺癌
Circulating tumor-derived biomarkers in lung cancer
CorrespondingAuthor: Klaus Pantel Email: pantel@uke.uni-hamburg.de
Abstract
The NIH Biomarkers Definition Working Group defined a biomarker as “a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacological responses to a therapeutic intervention” (1). In lung cancer, an enormous research effort is underway related to biomarkers in airway epithelial cells, sputum, breath, urine and blood for early diagnosis or prediction of high risk. Here, we will focus on blood as the source of biomarker research and in particular comment on circulating tumor cells (CTCs) and circulating nucleic acids.